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Abstract
This study explored experiences, perceptions and views
among World Health Organization (WHO) staff about
the changes, progress and challenges brought by the
guideline development reforms initiated in 2007. Thirtyfive semistructured interviews were conducted with
senior WHO staff. Sixteen of the interviewees had in-depth
experience with WHO’s formal guideline development
process. Thematic analysis was conducted to identify key
themes in the qualitative data, and these were interpreted
in the context of the existing literature on WHO’s guideline
development processes. First, the reforms were seen to have
transformed and improved the quality of WHO’s guidelines.
Second, independent evaluation and feedback by the
Guidelines Review Committee (GRC) was described to have
strengthened the legitimacy of WHO’s recommendations.
Third, WHO guideline development processes are not yet
designed to systematically make use of all types of research
evidence needed to inform decisions about health systems
and public health interventions. For example, several
interviewees expressed dissatisfaction with the insufficient
attention paid to qualitative evidence and evidence
from programme experience, and how the Grading of
Recommendations Assessment, Development and Evaluation
(GRADE) process evaluates the quality of evidence from nonrandomised study designs, while others believed that GRADE
was just not properly understood or applied. Fourth, some
staff advocated for a more centralised quality assurance
process covering all outputs from WHO’s departments
and scientific advisory committees, especially to eliminate
strategic efforts aimed at bypassing the GRC’s requirements.
Overall, the ‘culture change’ senior WHO staff called for over
10 years ago appears to have gradually spread throughout
the organisation. However, at least two major challenges
remain: (1) ensuring that all issued advice benefits from
independent evaluation, monitoring and feedback for quality
and (2) designing guideline development processes to better
acquire, assess, adapt and apply the full range of evidence
that can inform recommendations on health systems and
public health interventions.
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Introduction
In 2007, the World Health Organization
(WHO) embarked on far-reaching reforms

Key questions
What is already known?
►► Previous studies of WHO’s guidelines have primarily

focused on the outputs of the guideline development processes, while the experience of WHO staff
with these processes have received relatively less
attention.

What are the new findings?
►► WHO’s Guidelines Review Committee—which over-

sees formal guideline development at WHO—is a
key institutional mechanism for securing independent evaluation, monitoring and feedback.
►► WHO’s guideline development processes (especially
about complex interventions) are not yet designed
to systematically make use of all types of relevant
research evidence.
►► WHO’s technical departments and scientific advisory committees still issue guidance without subjecting these to WHO’s formal guideline development
processes.

What do the new findings imply?
►► WHO should promote systematic sharing of experi-

ences and learning among its departments, systematically apply the full range of research evidence and
consider centralised quality assurance processes for
all products with normative content.
►► Other technical health agencies and institutions
could learn from WHO’s mechanisms for ensuring
independent evaluation, monitoring and feedback
for process and quality in guideline development.

of its guideline development process. The
major driving factor was a study published
by Oxman, Lavis and Fretheim in The Lancet
that identified at least four flaws in the agency’s guideline development processes.1 First,
systematic and transparent methods for
retrieving, appraising, synthesising and interpreting evidence were rarely used. Second,
WHO’s guideline development processes
rarely involved methodologists or representatives of populations affected by the
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Figure 1

Key events and changes during the evolution of WHO’s guideline development process.

recommendations. Third, limited efforts were made to
adapt global recommendations to local needs, conditions, resources, costs and values. Fourth, dissemination
and implementation strategies, and rigorous evaluations
of these, were largely absent.
WHO quickly acknowledged the criticism and promised an immediate response.2 Several key changes to
strengthen WHO’s guideline development process
followed (figure 1). A new guideline development
process was set up to involve different groups—internal
and external to the agency—with specified roles and
responsibilities (box 1). To ensure a transparent and
evidence-informed decision-making process for every
formal guideline issued by the agency, WHO established
a Guidelines Review Committee (GRC). The GRC was set
up in 2007 as a scientific oversight committee tasked with
independently reviewing all guideline proposals from
WHO’s departments prior to initiating the guideline
development process and to approve the final guidelines
once completed. An essential part of ensuring transparency and rigour was prioritising the use of systematic
reviews to inform guideline development and the use
of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool.3 The GRADE
approach represents a systematic and transparent framework for appraising the quality of the evidence informing
recommendations and making judgements about the
strength of the recommendations. Two editions of a Handbook for Guideline Development have also been produced.4 5
It is now over 10 years since WHO implemented its
guideline development reforms. Previous studies of
WHO’s guidelines have focused on the outputs of guideline development processes, including assessing the
quality of the evidence underlying recommendations,6–10
identifying explanations for issuing discordant recommendations11 12 and identifying challenges with implementing the GRADE approach.9–11 13–15 Only one study,
published 5 years ago, focused on examining the views
and perceptions of WHO staff about the reforms.9 That
study identified mixed views about whether WHO needed
2

a single quality assurance mechanism, and uncertainties
and lack of capacity among staff in applying the GRADE
approach, concluding that quality assurance standards
set by the GRC were yet to be fully embedded within the
agency.9 This study builds on previous studies and was
conducted as part of a larger research project examining
the design and effectiveness of WHO’s scientific advisory
committees. Specifically, the research objectives of this
study were to investigate WHO staff’s experience with,
perceptions of and views about the changes brought by
WHO’s guideline development reforms, the progress
and impact of these reforms to date, and key challenges
that need to be addressed.
Methods
Study design
This study used a qualitative study design involving primary
data collection consisting of semistructured interviews
with senior WHO staff. The analytical approach involved
identification and interpretation of themes in the qualitative data describing key experiences, perceptions and
views about WHO’s guideline development reforms. This
study did not operate with explicitly defined theoretical
frameworks to guide the scope of the study, the specification of the research questions, or support interpretation; instead, the major themes identified in the qualitative data were interpreted in the context of the existing
literature on WHO’s guideline development process and
guideline development more generally.
To identify major themes in the qualitative data, we
followed the five-cycle process described by Yin (described
in greater detail in the Data analysis section).16 Yin does
not explicitly describe this process as ‘thematic analysis’; yet this analytical process involves identification of
themes capturing ‘something important about the data in
relation to the research question’,17 and representing an
‘idea or concept that captures and summarises the core
point of a coherent and meaningful pattern in the data’.18
Accordingly, the methodological approach described
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Box 1

Key features of WHO’s guideline development process*

What is a WHO recommendation?
WHO describes a recommendation to tell ‘the intended end-user of the guideline what he or she can or should do in specific situations to achieve
the best health outcomes possible, individually or collectively’ and to offer ‘a choice among different interventions or measures having an anticipated
positive impact on health and implications for the use of resources’.
Furthermore, WHO’s handbook emphasises that ‘guidelines must have a clearly defined target audience (end-user) which is identified early in the
guideline development process’ and that ‘the recommendations need to be tailored to that audience’. The target audience of guidelines are typically
either policy-makers, managers in the health sector or health professionals. WHO recommendations help end-users ‘make informed decisions on
whether to undertake specific interventions, clinical tests or public health measures, and on where and when to do so, and to help the user to select
and prioritise across a range of potential interventions’.

Who initiates a WHO guideline development process?
Technical departments in WHO initiate and coordinate the guideline development process. WHO generally develops guidelines in response to needs
expressed by its Member States, WHO country offices, external experts or other stakeholders for guidance on a clinical or public health problem or
policy area.

What type of committees are established and how are these constructed?
Four different groups are established when developing WHO guidelines: (1) a steering group, (2) a guideline development group (GDG), (3) an external
review group and (4) a systematic review team.
1. The steering group is led by the responsible technical officer from the technical department overseeing the guideline development process. Among
its responsibilities include drafting the scope of the guideline, identifying the systematic review team and guideline methodologist, and submitting
the planning proposal to the Guidelines Review Committee (GRC). The steering group is usually exclusively composed of members from all WHO
departments and regional offices whose work deal directly with the topic of the guideline. In cases where the guideline is developed jointly with
another UN agency, individuals from that agency will also be members of the steering group.
2. The GDG is composed of external experts, and its central task is to develop the evidence-informed recommendations. Its composition should reflect the technical skills, geographic representation and diverse perspectives (including end-users and representatives of people and communities
affected by the recommendations) needed to produce the guideline. Its membership does not include employees of WHO or other UN agencies. The
GDG is established early in the process once the steering group has defined the general scope and target audience of the guideline and drafted key
questions. The GDG is responsible for finalising the scope and key questions of the guideline. Members do not receive any financial compensation
other than for direct expenses associated with their work on the guideline.
3. The external review group is composed of technical experts, end-users, programme managers, advocacy groups and individuals from communities
affected by the recommendations. Similar to the GDG, the external review group should be balanced in terms of geography and gender and should
involve diverse perspectives. If important perspectives and stakeholders are missing from the GDG, these should be represented in the external
review group. Members of the external review group can be asked to participate in different stages of the guideline development process, such
as reviewing the guideline’s scope and key questions, reviewing the final guideline for errors or missing data and commenting on implications for
implementation.
4. The systematic review team are usually external groups commissioned by WHO to undertake systematic reviews of the evidence base underpinning
the key questions identified by the steering committee and the GDG. Ideally, the systematic review team is identified early and involved in formulating
the key questions and establishing a reasonable scope for the guidelines.

What role does the methodologist play during the guideline development process?
WHO Handbook for Guideline Development recommends that at least one methodologist—defined as an expert in guideline development processes
and methods—should be involved in the development of WHO guidelines. The methodologist should be an expert in systematic reviews, GRADE
(Grading of Recommendations Assessment, Development and Evaluation) and translating evidence into recommendations. The process should recruit
them early to enable their participation in planning, scoping and developing the key questions. During the GDG meetings, the methodologist supports
the GDG to ensure that recommendations are informed by the evidence in a transparent and explicit manner.

What is the composition and role of the GRC?
The GRC was established by WHO’s Director General in 2007 to ensure that WHO guidelines are of high quality, are developed using a transparent
and explicit process, and to the extent possible, are evidence-based. The GRC is composed of approximately 30 individuals. Five of these are external,
while the remaining are WHO staff from headquarters and regional offices (Susan L Norris, personal communication, 2018). WHO’s Member States do
not have representatives in the GRC, and the GRC members serve in their individual capacity (Susan L Norris, personal communication, 2018). The
GRC meets monthly to review submitted documents. All WHO publications containing recommendations must be approved by the GRC according to
WHO policies and procedures. The GRC reviews every WHO guideline at the initial planning stage and again after the recommendations have been
developed and the guideline document has been finalised and edited. GRC approval is part of WHO’s internal clearance processes for the publication
of guidelines. The GRC is supported by the GRC Secretariat, which provides WHO staff with technical advice on guideline development, sets
benchmarks and evaluates guideline development processes.
*All content was gathered from WHO Handbook for Guideline Development (Second edition).14

below resembles Braun & Clark’s six phases of thematic
analysis: (1) familiarisation with the data, (2) coding, (3)
searching for themes, (4) reviewing themes, (5) defining

and naming themes and (6) writing up.17 Moreover, the
way our findings have been identified, interpreted and
presented under ‘Results’ is broadly consistent with the
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Box 2 Two general recommendations and three specific
actions for WHO
Two general recommendations
►► Guideline development processes in technical health agencies and

institutions should learn from WHO’s vast experience with implementing independent evaluation, monitoring and feedback for process and quality to ensure the legitimacy of recommendations.
►► Guideline development processes at WHO should be designed to
better acquire, assess, adapt and apply the full range of research
evidence that can inform recommendations about health systems
and public health.

Three specific actions for WHO
►► WHO should foster the systematic sharing of experiences and learn-

ing among its departments that are or are planning to engage with
guideline development processes so as to promote continuous professional development of its staff.
►► WHO should share its experience externally (such as with the
GRADE (Grading of Recommendations Assessment, Development
and Evaluation) Working Group and its subgroups) as part of an
effort to further optimise the guideline development processes to
meet the needs of health systems and public health interventions
(eg, complex interventions).
►► WHO should consider whether outputs from scientific advisory
committees that currently operate outside of the formal guideline
development rules should be subject to a centralised quality assurance process.

qualitative descriptive approach described by Sandelowski.19 20 Here, the identified themes present a comprehensive and rich summary of experiences responding to
the research objectives. However, Sandelowski proposes
the use of content analysis as the main analytical
approach in a qualitative descriptive study, a term used
interchangeably with thematic analysis, but which many
consider to be two distinct ways of approaching qualitative data analysis.21
The COnsolidated criteria for REporting Qualitative
research (COREQ) was used to report on the characteristics of the research team, study design and data analysis
(online supplementary file S1).22 COREQ was originally
developed to promote transparent and comprehensive
reporting of qualitative health research involving the
use of interviews and/or focus groups to explore preferences and needs of clinicians, healthcare providers,
policy-makers and patients. However, its relevance goes
beyond research on interactions within healthcare systems
since COREQ’s items clarify various choices important
for understanding the study design, the collection and
the interpretation of qualitative data more generally.
Document review
To gain a deeper understanding of WHO’s guideline
development process, inform the development of the
study’s research objectives, and help interpret the main
findings in a broader context, a comprehensive literature
review was conducted to identify and summarise research
articles that have previously examined WHO’s experience
4

with its guideline development reforms. PubMed, SSRN
and Web of Science were searched combining the
keywords ‘World Health Organization’ and ‘guideline
development’. Three additional studies not identified
through this search were also included.6 8 11 A summary
of all included studies’ methodologies and key findings
are available in online supplementary file S2. Studies that
did not evaluate the guideline development process, but
only described the development of specific guidelines,
were excluded.23
Semistructured interviews
This research project and the proposed research questions
were discussed with one very senior leader within WHO,
who made an initial email introduction inviting directors
of technical departments and coordinators of various technical programmes to participate in the study. These directors and coordinators either agreed to participate themselves, forwarded the request to other WHO staff responsible for convening scientific advisory committees within
their respective departments or did not respond. A list of 68
potential WHO interviewees was generated through purposive and snowball sampling, and all of these were invited to
participate in the study. Of these 68 people, 1 was no longer
at WHO, 3 felt their work was not relevant for the study, 3
declined due to busy schedules, 6 forwarded the request to
other staff they deemed more suitable for the study and 14
did not respond to the invitation. In total, 41 senior WHO
staff were interviewed between March and June 2016. Six of
these interviews were conducted by SJH (male, PhD, lawyer)
at WHO headquarters in Geneva to pilot the scope and relevance of the study, gain clarity on the range of scientific advisory committees at WHO and revise the interview questions
to maximise their clarity and probative value. These pilot
interviews did not intend to explore the inner workings of
WHO’s guideline development processes; accordingly, these
six interviews were not audio recorded and transcribed,
and the data was not included in the formal analysis. The
remaining 35 interviews were conducted by UG (male, PhD,
physician). Both authors have previous experience working
with processes informing WHO guidelines and strategies,24–26 and conducting and publishing studies involving
qualitative methods to explore research questions on the
role of national and international institutions in global
health.27 28
Every participant was sent an email prior to the interview introducing the interviewer and the project, which
included a concept note about the project. Thirteen
interviews were conducted in-person at WHO’s headquarters in Geneva and 22 interviews were conducted by
telephone. The interview questionnaire (online supplementary file S3) was designed to address key questions
pertaining to the design and effectiveness of scientific
advisory committees. The interviews were conducted
using a semistructured format, permitting some iterations to the questions depending on the response of the
interviewees, and flexibility to address interesting themes
emerging from responses. Participants were interviewed
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individually, except for three participants who were
based in the same WHO department and interviewed
together. Only the interviewees were present in the room
during the interviews. No repeat interviews were carried
out. With informed consent, the 35 interviews were audio
recorded, transcribed and anonymised. The interviews
lasted between 45 and 60 min. We categorised interviewees into five main groups:
1. Directors of technical departments who had experience overseeing development of WHO guidelines and
other forms of scientific advice (n=7).
2. Coordinators and team leaders of technical units within departments with responsibilities for managing
guideline development processes or scientific advisory committees, including WHO’s expert committees
(n=19).
3. Technical officers responsible for supporting guideline development processes or other types of scientific
advisory work at WHO (n=4).
4. WHO staff with other roles, such as senior advisory
roles or organisational management (n=3).
5. Staff with leadership positions in programmes or partnerships hosted by WHO and with responsibilities for
overseeing scientific advisory work (n=2).
Of these 35 interviewees, 16 had in-depth experience
with WHO’s guideline development processes, while
the remaining interviewees primarily dealt with other
types of scientific advisory functions at WHO (such as
WHO’s expert committees or scientific and technical
advisory groups). On average, the interviewees had
13 years of experience working at WHO (range 0.5–32
years). Interviewees had experience working on various
technical issues, including antimicrobial resistance, child
health, environmental health, essential medicines and
pharmaceutical policy, health workforce, HIV/AIDS,
humanitarian response, immunisation and vaccine safety,
maternal and reproductive health, non-communicable
diseases and nutrition, polio, tobacco control, tuberculosis and social determinants of health.
Data analysis
The process for identifying major themes in the qualitative data followed the general five-cycle process described
by Yin,16 which represents an iterative approach involving
five phases: (1) compiling, (2) disassembling, (3) reassembling, (4) interpreting and (5) concluding. While each step
addresses specific aspects of data analysis, we moved back
and forth between phases 2 and 4 as part of continuously
revisiting the accuracy of initial coding and interpretation
of the data. Compilation consisted of transcribing and further
deidentifying each audio recording, including removing
specific mentions of names, titles and departments, which
may indirectly identify the interviewee. Disassembling
consisted of open coding where level 1 codes, including
in vivo codes, were assigned to words, phrases and larger
fragments of each interview transcript. During this phase,
relationships between level 1 codes from different interviews were identified and assigned level 2 codes, thereby

facilitating an incremental understanding of the major
themes from across the interviews. The reassembling phase
consisted of bringing level 1 and level 2 codes together
to identify themes representing a central concept and/or
message that captured recurring patterns observed across
the interviews. The codes and patterns deemed most relevant
for the study questions were continuously refined through
an iterative process and by using the constant comparison
method inspired from grounded theory.16 We observed that
the last five to six interviews only introduced a few new codes
and no new major themes, which we used as the indication
for reaching data saturation. During the interpretive phase,
we used the reassembled data to write a narrative around the
study questions, while continuously assessing whether revisiting the disassembling and reassembling phases was needed
to recompile the data. Field notes and memos documenting
observations and reflections during and after the interviews
(eg, whether interviewees emphasised particular aspects
or the investigator’s initial comparisons of issues raised in
the interview with those raised in previous interviews) were
considered during all stages of the analysis.
The qualitative data was transcribed and coded by one
investigator. After initial identification of level 1 and level 2
codes and their associated themes by UG, the findings were
discussed in detail with the second investigator (SJH) and
refined until agreement was reached about the fit of the
codes with the identified central themes and messages. We
provided interviewees with two opportunities to comment,
make suggestions or raise any concerns with our data analysis and interpretation. First, we sent each interviewee the
full transcript and a 1–2 page summary of their interview.
These summaries were sent approximately 1 year after the
interviews were conducted. Second, we sent all interviewees
an early draft of this manuscript prior to submitting it to
BMJ Global Health. Overall, 14 of 35 interviewees confirmed
receiving the summary and/or the manuscript, while the
remaining interviewees did not respond. One interviewee
explicitly expressed disagreement with how the findings
were presented, although did not object to the content.
To further validate our findings, we sent the manuscript to
two WHO staff with extensive experience with the agency’s
guideline development processes—but who were not interviewed for this study—for their feedback. They expressed
that they recognised the main findings of the study.
Four major themes pertaining to WHO’s guideline development process were identified from the analysis of the
interviews. The qualitative codes related to these themes are
presented in table 1. During the concluding phase, the interpretation of the main empirical findings formed the basis
for two main recommendations proposed under discussion.
Ethics
An exemption to ethical review was granted for this study
by the University of Ottawa’s Office for Research Ethics
because the study was considered a programme evaluation in accordance with Canada’s Tri-Council Policy
Statement (TCPS2) on the Ethical Conduct for Research
Involving Humans.29

Gopinathan U, Hoffman SJ. BMJ Glob Health 2018;3:e000716. doi:10.1136/bmjgh-2018-000716

5

BMJ Glob Health: first published as 10.1136/bmjgh-2018-000716 on 8 September 2018. Downloaded from http://gh.bmj.com/ on 20 September 2018 by guest. Protected by copyright.

BMJ Global Health

Table 1 Major themes and corresponding qualitative codes
Themes

Level 2 codes

Level 1 codes

WHO’s guideline development
Triggers of the reform
reforms represented a
Impact of the reform
transformational shift in its
approach to producing clinical and
public health recommendations

Dominance of expert opinion
Handbook with comprehensive guidance
Transformed WHO’s guideline development
process
Institutionalisation of evidence-based principles
More consistent use of systematic reviews

Independent evaluation and
feedback by the GRC has
strengthened the legitimacy
of the decision-making
processes underlying WHO’s
recommendations

Independent evaluation strengthens
legitimacy

WHO guideline development
Challenges with retrieving and
efforts are not yet designed to
appraising evidence to inform
systematically make use of all
complex interventions
relevant research evidence needed
to inform decisions about complex
interventions

GRC process has helped recommendations stand
up to criticism

Nature of WHO guidelines becoming more
complex
Evidence from beyond RCTs needed to inform
recommendations
Challenges with formulating systematic review
questions that capture broader range of evidence

Challenges with and perceptions
about GRADE

GRADE struggling with qualitative evidence
Dissatisfaction with how GRADE evaluate nonrandomised study designs
Challenging with rigid application of GRADE
GRC process perceived rigid/complicated
Misperceptions about GRADE only being
applicable to evidence from RCTs
Need for more sophisticated understanding of
GRADE

Dialogues to address challenges

Increasing awareness within GRC about
difficulties
Constructive dialogue with GRC and
methodologists crucial
GRADE approach evolving to become more
applicable to broader range of evidence

WHO’s guideline development
Bypassing of formal guideline
reforms do not currently apply to
development process
all outputs published from all of
WHO’s technical units and scientific
All issued guidance could benefit from
advisory committees
independent evaluation, monitoring
and feedback

Guidance being issued outside process overseen
by GRC
Tempting to circumvent GRC process
Disorganised approach to managing guidance
produced outside GRC requirements
Similar quality assurance needed for other
guidance

GRADE, Grading of Recommendations Assessment, Development and Evaluation; GRC, Guidelines Review Commitee; RCT, randomised
controlled trial.

Results
WHO’s guideline development reforms represented a
transformational shift in its approach to producing clinical
and public health recommendations
It was widely recognised among WHO interviewees
that earlier criticisms of WHO’s old guideline development process were appropriate and that reforms
were needed due to the widespread reliance on
expert opinion and ad hoc processes rather than
6

structured processes informed by synthesised research
evidence. For example, according to one WHO
interviewee:
… it was felt that this is just a bunch of expert opinions that
is coming together. Who you happen to pick on that committee was going to define what the outcome was going
to be. It was felt that WHO was handpicking and forcing
themselves to a particular outcome that a small group of
people at WHO wanted. (WHO Interviewee 9)
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The consistent use of systematic reviews was described
to be “the major change introduced with the guideline process”, with the aim being to “stop WHO relying
only on expert opinion” (WHO Interviewee 16). The
reformed guideline development process was described
to represent a transformational shift in how WHO developed clinical and public health recommendations, with
one interviewee arguing that “how things are being
done now is totally different from ten years ago” (WHO
Interviewee 22). It was felt that the reforms overall had
improved the quality of WHO’s recommendations:
Yeah, it is a long process that costs time and money because
you have to commission the systematic reviews which take
time. But then, at the end, you have a document and no
one can come and tell you, ‘OK, why this?’ because you
have the evidence, you can show the evidence supports the
recommendations. I think that is a good thing for WHO.
(WHO Interviewee 18)

Independent evaluation and feedback by the GRC has
strengthened the legitimacy of the decision-making
processes underlying WHO’s recommendations
Several interviewees observed that guidelines from WHO
frequently meet opposition, especially when recommendations challenge commercial interests and WHO subsequently face “strong push-back from the industry” (WHO
Interviewee 13). Accordingly, many interviewees highlighted the important role of the GRC as a quality assurance mechanism for recommendations from WHO.
Interviewees described the GRC to be an institutional
mechanism for independent evaluation and feedback
to ensure that appropriate procedures were followed. It
was reported that the GRC had contributed to strengthening the legitimacy of decision-making processes underlying WHO’s recommendations. For example, two interviewees expressed:
It [the GRC] safeguards the procedural issues to say the
members of the guideline development group were all
vetted for conflict of interest, the meeting was done according to the procedures of the GRC, so we have that assurance. Even when we have serious challenges, letters of
complaints, for example written to ethics committees, that
helped us make our case on the process, but also on the
technical recommendations. (WHO Interviewee 14)
As long as you have something like a GRC mechanism that
screens everything in the end, where people can go and
say ‘this is how we did it’, these are the members, this is the
process, and so it has been done well. (WHO Interviewee
22)

WHO guideline development efforts are not yet designed to
systematically make use of all relevant research evidence
needed to inform decisions about complex interventions
Although WHO interviewees generally expressed support
for the guideline development reforms, many interviewees argued that the guideline development process
in its current form is not designed to consider the full

range of evidence that can inform health systems and
public health recommendations. Two major challenges
were highlighted by the interviewees.
First, some interviewees expressed that research questions for systematic reviews could be formulated very
narrowly such that they did not capture the broader
range of evidence needed to make nuanced recommendations about health systems and public health issues.
One interviewee explained:
I think that in some cases, there most probably is a tendency to pose too many peephole questions in areas where
you’re not going to have the evidence, so you’re going
through your systematic review and the outcome is very
confusing. (WHO Interviewee 20)

Another interviewee described the challenge to be
that “the definition of a systematic review is being set so
narrowly that it’s hard to bring in other kinds of relevant
information to the table” (WHO Interviewee 9). Accordingly, interviewees emphasised the need for guidelines
about health systems and public health interventions to
consider evidence generated by non-randomised study
designs and systematically documented programme
experience, especially in order to produce guidance
about how to implement and scale-up interventions. For
example, two WHO interviewees explained:
… because some of the richness of how you scale it up and
make it work in the field is quite distinct from RCTs [randomised controlled trials], or when you review RCTs, you
basically exclude a vast amount of knowledge which is powerful knowledge in the field. (WHO Interviewee 15)
It is becoming challenging because on clinical interventions or something very medical, RCTs are fine and they
produce the right sort of evidence. Increasingly, we are
producing evidence around programmatic issues, service
delivery programs, health systems functioning, social interventions, behavioural change, etc, and when you are looking at providing evidence on how programs should function, RCTs are generally not the best source of evidence.
(WHO Interviewee 28)

Second, several interviewees expressed dissatisfaction
over the current use of the GRADE approach for evaluating the quality of the evidence informing guideline development, raising two main concerns. The first was about
GRADE being designed to assess the evidence for the effectiveness of interventions, but struggling “with how to interpret qualitative research findings” (WHO Interviewee 14).
The second was about how the GRADE process rated the
quality of evidence generated from non-randomised study
designs and that most often the quality of evidence from
these studies was rated as ‘low’. It was argued that in these
cases, consistent results from multiple well-designed observational studies should lead to a more favourable rating of
the quality of the evidence, especially when interventions
and policies cannot be tested with randomised controlled
trials (RCTs) due to ethical, legal or logistical reasons. For
example, two interviewees expressed:
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I still have a problem with, you know, if you have ten studies by ten different investigators, finding the same results,
[and] not giving that benefit versus if you have only one
study. Think about it the way you want, but for me there is
more evidence with ten different studies from ten different
investigators with ten different methodologies, so we try to
advocate for increasing quality because of the consistency. But currently consistency is used only to downgrade.
(WHO Interviewee 12)
It does mean that when you score the grade using the
GRADE tool, because it’s not a randomized control trial, it
tends to say that the ‘oh, the level of evidence is low’, when
this is going to be always the highest-level of evidence that
you can have and it’s been replicated and done in many
other places. (WHO Interviewee 31)

In relation to these concerns, interviewees expressed
“there is too much rigidity in the way it’s currently handled”
(WHO Interviewee 12) and that some methodologists had
“pushed a very rigid approach on the organization” (WHO
Interviewee 16). Similarly, another interviewee argued that
more flexibility and a better balance have to be found in
order to adequately make use of all available evidence:
I think the WHO swung the pendulum too far to the opposite of the extreme, trying to make things so pure and so
unbiased that it left out the depth of understanding of the
issues, and left out the depth of understanding the literature around an issue … We don’t want it to be like it was
before, but I think we pushed it too far, we need to come to
something that is a little bit more balanced between those
two approaches. (WHO Interviewee 9)

However, others argued that the “GRADE process does
allow for consideration of all types of evidence,” and that
“it’s most probably the interpretation of the GRADE
process that most probably distracts from a reasonable
decision-making process” (WHO Interviewee 20). It was
argued that the guideline development process and the
GRC suffered from an internal perception problem in
that “people think GRADE means RCTs” and that “it’s a lot
about people being a lot more sophisticated in their understanding of it” (WHO Interviewee 16). In line with this,
other interviewees expressed that a constructive dialogue
with the GRC and methodologists, and guidance about the
GRADE approach had proved helpful in improving their
understanding about the guideline development process
and adapting it to their specific context and needs:
Then the new methods expert that we had was much more
flexible and was willing to work with us to see how GRADE
can be applied to the kind of the studies which are mainly
providing the evidence from our area of work. (WHO Interviewee 7)
I think that it can look very difficult and challenging, but
when you discuss with the committee [GRC], they can give
you ways to address it and adapt it to your problem. (WHO
Interviewee 18)

Several interviewees described that conversations
were occurring both within various departments—and
between those managing guideline development efforts
8

and the GRC—about this challenge, but that it remained
to be seen how the agency and the GRC will ultimately
deal with it:
I think the GRC has become more open to those kinds
of dialogues, but it’s kind of outside the normal process,
so you have to set it up as ‘here’s an exception, and why
do we have to justify this exception’. And I think we are
moving in the right direction, but it is already a problem that the whole structure is kind of set up, it has to
be handled as a special case as opposed to setting it up
to bring a broad body of evidence to the table. (WHO
Interviewee 9)

WHO’s guideline development reforms do not currently apply
to all normative outputs published from all of WHO’s technical
departments and scientific advisory committees
Many interviewees reported being involved with WHO
advisory bodies known as ‘scientific and technical advisory
groups’. These bodies were described as “more informal
than a guidelines review group because it’s not tasked with
making necessarily policy recommendations on treatments
and use of diagnostics” (WHO Interviewee 15). Another
interviewee characterised these bodies as not primarily
dealing with scientific questions and technical issues, but
rather the strategic direction of various WHO programmes:
It’s an advisory body, and it’s not just science and technical
issues but it’s also strategic issues for our programmatic response, so in that way it operates slightly differently from
a group that would convene around one piece of scientific
policy. But it broadly reflects on guidelines produced and
the overall strategic direction for our program and fulfilling WHO’s core functions. (WHO Interviewee 17)

However, several interviewees described these bodies as
also producing guidelines and policy recommendations
that should be subjected to the formal guideline development process. For example, one interviewee expressed
that “from time to time, we most probably are putting
out guidance that should really be graded for guideline
recommendations” (WHO Interviewee 19). Interviewees
also described cases of strategic attempts by WHO staff to
circumvent the mandated guideline development process
that is quality assured by the GRC. One interviewee raised
that the resources and rules associated with the guideline
development process could tempt staff to frame guidance
documents in ways that enabled them to bypass the formal
route, which risked issuing WHO recommendations without
bringing all the available scientific evidence to the table:
So you’re trying to figure out how do I frame this so that it
doesn’t really sound like a WHO guideline, so that I don’t
have to deal with all that process … Except that if you
don’t have to go through the rigorous process, then you’re
kind of on your own, you can do whatever you want to do.
There’s no oversight, there’s no guidance on what ought to
be part of that, and I think you end up not making the best
recommendations. (WHO Interviewee 9)

Another interviewee expressed concerns about the agency
having a “completely disorganized approach to managing
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anything outside of the GRC or the expert committee
processes” and that there exist “examples of groups that
are informal that do not follow any procedures” (WHO
Interviewee 16). Further concerns were raised on whether
these scientific advisory committees produced advice that
was in keeping with WHO’s policies and standards (WHO
Interviewee 1). It was suggested that there is scope for these
outputs to be captured by a more centralised quality assurance process that cover all WHO outputs:
If GRC was being set up again, you would try to say everything goes through the committee, you would probably
have a slightly different looking committee, and a slightly
different handbook, but the bypass route should not be allowed. (WHO Interviewee 16)

Discussion
This study aimed to understand how WHO has responded
to the reforms made to its guideline development process
over 10 years ago, including the major changes it made in
2007, the progress and impact of these changes to date,
and key challenges that need to be addressed. Informed
by the semistructured interviews with WHO staff and
previous studies on WHO’s guideline development
process, we propose and discuss two recommendations
that can inform efforts to improve the guideline development efforts of technical health agencies like WHO and
others at the local, national and international levels.
Recommendation 1: Guideline development processes in
technical health agencies and institutions should learn from
WHO’s vast experience with implementing independent
evaluation, monitoring and feedback for process and quality
to ensure the legitimacy of recommendations
One major factor contributing to the legitimacy of a
health recommendation is the underlying evidence base,
or in other words, the extent to which recommendations are consistent with the quality of available research
evidence. Our study did not quantitatively address this
question, but other studies suggest that there is still room
for WHO to improve. For example, one study found that
over 50% of strong WHO recommendations are based on
assessments of evidence that place low or very low confidence in effect estimates (known as ‘discordant recommendations’), with the majority of these being inconsistent with the GRADE approach.6 12
However, the strength of the evidence alone is insufficient to ensure the legitimacy of a recommendation.
A second major contributing factor to legitimacy is the
decision-making process through which the recommendations are developed.30 Good process is particularly
important in cases where recommendations might implicate commercial or ideological interests. A strategy that
interested actors often use to challenge the legitimacy of
recommendations, even in cases where the underlying
evidence base is strong, is to question the process by
which guidelines were generated, including the selection
of experts or the participation of relevant stakeholders.

One way of strengthening the legitimacy of decision-making processes and protecting recommendations from undue criticism is to ensure that the process
followed was subject to independent evaluation, monitoring and feedback for quality. WHO has over 10 years
of accumulated experience with implementing its GRC
mechanism, which can be seen as an internal quality
assurance mechanism augmented by external expertise.
Its assessments are made independently of WHO’s senior
management and its Member States. Accordingly, the
GRC can be seen to serve two roles: (1) represent an institutional mechanism for independent evaluation that can
strengthen the legitimacy of the decision-making process
underlying the recommendations and (2) by involving
staff internal to the agency support gradual institutionalisation of evidence-informed principles and processes.
Learning from WHO’s experience with implementing
independent evaluation, monitoring and feedback for
process and quality to ensure the legitimacy of recommendations can be relevant for other technical agencies
and institutions responsible for guideline development
on health issues.
Recommendation 2: Guideline development processes at
WHO should be designed to better acquire, assess, adapt and
apply the full range of research evidence that can inform
recommendations about health systems and public health
The second recommendation calls for adapting WHO’s
guideline development process to better enable assessment of the evidence base needed to inform health
systems and public health interventions, many of which,
if not all, are ‘complex interventions’.31 Unlike individual-level interventions which can more easily be evaluated
by randomising study participants to receive either treatment or control, many health systems and public health
interventions cannot be randomised for ethical, legal
or logistical reasons, even if governing decision-makers
are supportive of doing so. Accordingly, evidence from
non-randomised study designs—for example a well-designed observational study, quasi-experimental impact
evaluation or systematically documented evidence from
programme experience—may represent the highest
quality of evidence one can expect for a public health
or health systems intervention.9 32 This challenge is not
unique to guideline development processes at WHO
but has been debated at various points over the past
years.14 33–40 It represents an important factor explaining
why WHO interviewees raised concerns over the guideline development process not being flexible enough to
incorporate and appropriately evaluate evidence from
non-randomised study designs and qualitative studies.
Similar views have previously been reported to be held
by WHO staff9 and guideline panel members,11 41 and
confirmed by methodologists with experience serving on
guideline panels.15
Two design features of WHO’s guideline development process seem to particularly need adaptation to
fully incorporate the evidence base needed to inform
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recommendations. The first design feature is the use of
systematic reviews to critically appraise relevant research
underpinning WHO recommendations. Systematic
reviews are among the cornerstones of guideline development processes and are critical for reducing the
risk of bias and reaching reliable evidence-informed
conclusions. By way of background, systematic reviews
are commonly conducted by formulating a clear and
specific question most commonly using the PICO format
(population, intervention, comparison, outcome) and
by having explicit inclusion/exclusion criteria. This
rigorous approach helps to identify and include studies
that are comparable and able to respond to questions
about effectiveness of interventions (what works).36 This
approach works sufficiently well for evaluating the effectiveness of a medical treatment. However, many health
systems and public health interventions are ‘complex’
interventions, characterised by multiple interacting
components, requiring the involvement of different
organisational levels, having a number of different points
of interactions between interventions and the settings in
which the interventions are implemented and affecting
different outcomes.31 37 38 For complex interventions,
framing systematic review questions too narrowly and
relying solely on assessing evidence of effectiveness risks
excluding the broader range of relevant evidence needed
to inform recommendations. This includes evidence for
factors important for implementing an intervention,
for bringing an intervention to scale, for assessing the
resources needed to implement interventions across
different settings, for understanding the feasibility and
acceptability of an intervention, for identifying the
interactions among various components of complex
interventions and for probing the systems in which the
interventions were implemented.42 These represent
factors that are not easily identifiable if systematic review
questions are narrow and solely include experimental
intervention studies focused on safety and effectiveness.
Currently, the WHO Handbook for Guideline Development
do not offer comprehensive guidance for adapting the
PICO format or considering alternative frameworks
when dealing with systematic reviews for health systems
and public health interventions.14 In light of new tools
and frameworks for conducting systematic reviews for
complex interventions,43 WHO might consider adapting
its guidance.
The second design feature of WHO’s guideline development process that has led to it being viewed as inflexible involves the approaches and tools used to evaluate
the quality of the evidence base. At WHO, the GRADE
approach has been the main tool for assessing the
quality of the evidence underlying recommendations.
This study’s findings highlight three aspects associated
with GRADE that seem to have reinforced the view
among many WHO staff that guideline development
processes are not designed to incorporate a broader
evidence base. The first is an insufficient understanding
among many people involved in guideline development
10

processes about the purpose, utility and implementation of the GRADE approach. This was also highlighted
by Sinclair et al in their evaluation of WHO’s guideline
development process,9 suggesting that better understanding of GRADE among WHO staff involved with
guideline development needs continued attention. To
this end, guidance to promote a more sophisticated
understanding of GRADE has been issued (including
by the GRADE Working Group),40 but greater awareness and wider implementation is needed at WHO. The
second aspect is GRADE’s initial rating of certainty in the
evidence from non-randomised study designs as ‘low’.
This is a feature of GRADE that guideline developers
beyond WHO have raised concerns over, since in fields
where RCTs are sparse or not feasible, the quality of the
evidence rarely will be rated as ‘high’ or ‘moderate’13;
fortunately, this is a criticism that the GRADE Working
Group have noted and are seeking to address.44 The
third aspect is that GRADE was not designed to evaluate
the quality of evidence from qualitative studies, which
is increasingly recognised as crucial for informing decision-makers about the needs, values, perceptions and
experiences of stakeholders important for an intervention, and the system-level factors affecting implementation.41 45 The reliance, at least until very recently,
on GRADE as the sole tool for assessing the body of
evidence might have created a perception that guideline development processes are not intended to incorporate a broader evidence base, including qualitative
evidence. These concerns over GRADE raised by WHO
staff in our study align with challenges highlighted by
others.14 32 46 47
On all of these fronts, there have been recent developments worth noting. For evaluating non-randomised
study designs, the ROBINS-I tool (Risk Of Bias In
Non-randomized Studies-of Interventions) has been
developed, with further extensions planned.48 Using
ROBINS-I as part of GRADE assessments can enable
better comparisons of evidence from non-randomised
study designs and RCTs, as well as more detailed
assessments of different types of non-randomised
study designs (such as rating evidence from a well-designed interrupted time series studies higher than
conventional non-randomised study designs), thereby
addressing one of the major concerns raised by WHO
interviewees.
For evaluating the quality of qualitative evidence,
WHO has together with collaborators taken a leadership role. Its own guideline development process for
recommendations about optimising health worker
roles for maternal and newborn health expanded the
evidence base beyond safety and effectiveness,41 leading
to the development of a new approach for assessing the
confidence that can be placed in qualitative evidence—
the Grading of Recommendations, Assessment, Development and Evaluation—Confidence in Evidence
from Reviews of Qualitative Research (GRADE-CERQual) tool.49 GRADE-CERQual has later been further
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developed and implemented as part of WHO guideline development processes,45 addressing yet another
concern raised by WHO interviewees. Moreover, the
Evidence-to-Decision Framework developed by the
DECIDE project creates space for the assessment of
an intervention’s acceptability and feasibility and is
increasingly being used in WHO’s guideline development processes.50–52 Finally, the challenges with synthesising and assessing the quality of evidence for complex
interventions, and the need for guidance and tools
are increasingly recognised, both within and beyond
WHO.43 53
Specific actions for WHO
We identify at least three specific areas where action
could be taken by WHO (box 2). First, there should be
more frequent and systematic sharing of experiences
among WHO departments and between the GRC and
the various departments that develop guidelines. Such
sharing and continuous professional development for
WHO staff would help address the many issues raised by
this study and others.9 11 15 Second, the guideline development process should be further enhanced to meet
the needs of health systems and public health interventions, which is consistent with recent calls in peer-reviewed journals from senior WHO staff.54 It is therefore
timely that efforts are underway to examine extensions
to the GRADE approach,55 as well as efforts led by the
GRADE Working Group to integrate GRADE assessment with the use of tools such as ROBINS-1.44 Moreover, WHO has internally recognised this and other
challenges with its guideline development process56
and initiated its own process for improving retrieval,
synthesis and assessment of evidence on complex
health interventions, which might inform future
changes to the design of WHO’s guideline development
process.53
Finally, WHO should consider whether all products
containing advice and guidance that emerge from the
plethora of WHO’s technical departments and scientific advisory committees—many of which currently
operate outside of the GRC’s mandate—could benefit
from a centralised quality assurance process independent of WHO Member States, similar to what is
currently performed by the GRC for WHO’s formal
guidelines. This may improve quality and legitimacy,
but it will also require resources, time and planning.
On this front, a recent development is that WHO has
proposed in its draft 13th General Programme of Work
to ‘establish guiding principles and quality assurance
procedures for the design, formulation and dissemination/follow-up of all normative products (all normative
products, including strategies, road maps and global
action plans will be based on agreed standards and
reviewed independently, as is the case for technical
guidelines), including maximizing the use and engagement of top international experts’ 57—a proposal

informed by a 2017 review of WHO’s normative
functions.58
Strengths, limitations and reflections on study design and
data analysis
We identify three main strengths and two main limitations of this study. The first strength is the large
number of interviewees (n=16) who had experience
with WHO’s guideline development process, as well
as additional interviewees (n=19) working with other
structures that produce scientific advice (eg, expert
committees, scientific and technical advisory groups),
which enabled us to consider WHO’s broader context
when interpreting our findings. A second strength is
that the majority of the interviewees were senior WHO
staff who have been working for the agency since before
the guideline development reforms were initiated and
therefore were able to inform our study with their
experiences before and after the reforms. The third
strength is the diversity in technical areas represented
by the interviewees, which enabled us to identify themes
that were relevant to guideline development processes
across WHO’s technical areas. The invited WHO staff
who for various reasons decided to not participate in
this study did not, with respect to roles and technical
areas, differ from those who were interviewed since we
managed to recruit interviewees from various levels and
across the many technical areas of the agency. Overall,
our analysis was informed by a large amount of qualitative data consisting of diverse sets of relevant experiences accumulated over a long period of time.
The first main limitation is that the study was initially
conceived to examine the design features of WHO’s
scientific advisory committees in general, and not
specifically to evaluate WHO’s guideline development
reforms. We may therefore have overlooked asking
important questions that could have deepened insights
about WHO’s experience with its reformed guideline
development process. For example, while all interviewees emphasised the importance of diverse representation in guideline development groups, we did
not probe in detail their experience with involving
populations affected by the recommendations during
guideline development—which is another important
factor affecting the legitimacy of recommendations.
The second main limitation is social desirability bias—
that WHO interviewees may have responded in a way
that casts the agency in a favourable light, downplaying
internal weaknesses and challenges. However, the
majority of interviewees provided candid assessments
of the agency’s progress and challenges with guideline
development and producing scientific advice. Moreover, some also spoke rather critically of the agency, such
that we do not believe the results are unduly biased
in this way.
Finally, choices made during data analysis are worth
discussing in light of different views and traditions with
respect to improving reliability in qualitative research.
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In our study, both investigators discussed and reached
agreement about the identified themes and the fit of
the coding with these themes. However, we did not
implement independent coding by two investigators;
rather, one investigator undertook the initial coding
and identification of preliminary themes, which were
subsequently discussed and refined in dialogue with
the second investigator. This strategy may be seen as
a weakness by researchers who argue that multiple,
independent coding and calculation of inter-rater reliability is a prerequisite for rigour and trustworthiness
in qualitative research.59–61 However, our approach is in
line with strategies undertaken and advocated by many
qualitative researchers, including Braun & Clarke who
have developed an approach to thematic analysis which
closely resemble the analytical strategy undertaken in
this study.18 62 They and others argue that there is no
‘one’ accurate way of coding and interpreting qualitative data and that it is unrealistic to expect different
researchers to reach exactly the same insights from
qualitative data, since they may differ in disciplinary
backgrounds and theoretical starting points. What
remains important is full transparency about choices
made during data analysis so that others can evaluate
how these choices may have affected analysis and interpretation. Moreover, it remains important to otherwise
minimise the risk of misrepresenting the qualitative
data. To address the former, we have described our
approach to data collection and analysis in great detail
in the Methods section. To address the latter, we implemented participant checking. While less than half of
the interviewees responded to our queries, only one
interviewee raised objections with the way the findings
were presented. We assume, but cannot be completely
certain, that if other interviewees had similar objections, they would have expressed these after receiving
the interview summaries or the manuscript. Moreover,
two WHO officials who were not interviewed for this
study, but with extensive in-depth experience with
WHO’s guideline development process, reviewed the
manuscript and reported to recognise the experiences
and key challenges identified by our study. Overall, we
believe that the reported findings and interpretation
do not misrepresent the interview data, but accept that
these findings could be interpreted differently by other
researchers. We therefore invite continued debate on
issues raised by this study.

from independent evaluation, monitoring and feedback
for process and quality and (2) adapting its guideline
development processes to better acquire, assess, adapt
and apply the full range of evidence that can inform
recommendations.
Author affiliations
1
Department of Global Health, Division for Health Services, Norwegian Institute of
Public Health, Oslo, Norway
2
Oslo Group on Global Health Policy, Department of Community Medicine and
Global Health and Centre for Global Health, Institute of Health and Society, Faculty
of Medicine, University of Oslo, Oslo, Norway
3
Global Strategy Lab, Dahdaleh Institute for Global Health Research, Faculty of
Health and Osgoode Hall Law School, York University, Toronto, Ontario, Canada
4
Department of Health Research Methods, Evidence, and Impact, and McMaster
Health Forum, McMaster University, Hamilton, Ontario, Canada
5
Department of Global Health and Population, Harvard T.H. Chan School of Public
Health, Harvard University, Boston, Massachusetts, USA
Acknowledgements The authors thank Susan L Norris from WHO’s GRC
Secretariat for responding to questions about WHO’s guideline development
processes and updating us about ongoing developments.
Contributors UG and SJH had the original idea for the manuscript. Data collection
was done by UG. Data analysis was done by UG and SJH. UG prepared the original
draft of the manuscript, and SJH provided input and comments on successive
drafts. Both authors read and approved the final draft.
Funding This study was completed as part of the research project 'Strengthening
International Collaboration for Capitalizing on Cost-Effective and Life-Saving
Commodities' (i4C) that is funded through the Research Council of Norway’s Global
Health & Vaccination Programme (GLOBVAC Project No 234608). SJH is additionally
funded by the Canadian Institutes of Health Research and the Ontario Government’s
Ministry of Research, Innovation & Science.
Competing interests UG has previously supported WHO’s guideline development
process on ‘Transforming and scaling up health professionals’ education and
training’ as an intern in 2011 and led a multicountry case study for the Norwegian
Knowledge Centre for the Health Services in 2011–2012, which informed the
development of WHO’s recommendations on ‘Optimizing health worker roles
for maternal and newborn health.’ SJH has previously worked for WHO. Both
authors have previously published articles examining WHO’s role in global health
governance.
Patient consent Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement At the time of data collection, consent was not obtained
from the interviewees to share the qualitative data beyond what is contained in this
article. We are, therefore, unable to provide access to the raw data.
Open access This is an open access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited, appropriate credit is given, any changes made indicated, and the
use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

References

Conclusion
Since WHO initiated reforms to its guideline development process, the agency has advanced towards a more
transparent and rigorous evidence-informed process
for crafting its recommendations. The ‘culture change’
senior WHO staff called for over 10 years ago appears
gradually to have spread throughout the agency.2
However, at least two major challenges remain for
WHO: (1) ensuring that all issued guidance benefits
12

1. Oxman AD, Lavis JN, Fretheim A. Use of evidence in WHO
recommendations. Lancet 2007;369:1883–9.
2. Hill S, Pang T. Leading by example: a culture change at WHO.
Lancet 2007;369:1842–4.
3. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging
consensus on rating quality of evidence and strength of
recommendations. BMJ 2008;336:924–6.
4. World Health Organization. WHO handbook for guideline
development. Geneva: World Health Organization, 2014.
5. World Health Organization. WHO handbook for guideline
development. Geneva: World Health Organization, 2012.
6. Alexander PE, Bero L, Montori VM, et al. World Health Organization
recommendations are often strong based on low confidence in effect
estimates. J Clin Epidemiol 2014;67:629–34.

Gopinathan U, Hoffman SJ. BMJ Glob Health 2018;3:e000716. doi:10.1136/bmjgh-2018-000716

BMJ Glob Health: first published as 10.1136/bmjgh-2018-000716 on 8 September 2018. Downloaded from http://gh.bmj.com/ on 20 September 2018 by guest. Protected by copyright.

BMJ Global Health

7. Burda BU, Chambers AR, Johnson JC. Appraisal of guidelines
developed by the World Health Organization. Public Health
2014;128:444–74.
8. Hoffman SJ, Lavis JN, Bennett S. The use of research evidence in
two International Organizations' Recommendations about health
systems. Healthc Policy 2009;5:66–86.
9. Sinclair D, Isba R, Kredo T, et al. World Health Organization guideline
development: an evaluation. PLoS One 2013;8:e63715.
10. Chang LW, Kennedy CE, Kennedy GE, et al. Developing WHO
guidelines with pragmatic, structured, evidence-based processes: A
case study. Glob Public Health 2010;5:395–412.
11. Alexander PE, Gionfriddo MR, Li SA, et al. A number of
factors explain why WHO guideline developers make strong
recommendations inconsistent with GRADE guidance. J Clin
Epidemiol 2016;70:111–22.
12. Alexander PE, Brito JP, Neumann I, et al. World Health Organization
strong recommendations based on low-quality evidence (study
quality) are frequent and often inconsistent with GRADE guidance. J
Clin Epidemiol 2016;72:98–106.
13. Akl EA, Kennedy C, Konda K, et al. Using GRADE methodology for
the development of public health guidelines for the prevention and
treatment of HIV and other STIs among men who have sex with men
and transgender people. BMC Public Health 2012;12:386.
14. Rehfuess EA, Akl EA. Current experience with applying the GRADE
approach to public health interventions: an empirical study. BMC
Public Health 2013;13:9.
15. Alexander PE, Li SA, Gionfriddo MR, Stoltzfus RJ, et al. Senior
GRADE methodologists encounter challenges as part of WHO
guideline development panels: an inductive content analysis. J Clin
Epidemiol 2016;70:123–8.
16. Yin RK. Qualitative research from start to finish. New York, NY:
Guilford Press, 2011:348.
17. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res
Psychol 2006;3:77–101.
18. Questions about thematic analysis [Internet]. https://www.psych.
auckland.ac.nz/en/about/our-research/research-groups/thematic-
analysis/frequently-asked-questions-8.html#e41676c2ec9a2c4c
aae1664a24aa3a0a (cited 3 Mar 2018).
19. Sandelowski M. What's in a name? Qualitative description revisited.
Res Nurs Health 2010;33:77–84.
20. Colorafi KJ, Evans B. Qualitative descriptive methods in health
science research. HERD 2016;9:16–25.
21. Vaismoradi M, Turunen H, Bondas T. Content analysis and thematic
analysis: Implications for conducting a qualitative descriptive study.
Nurs Health Sci 2013;15:398–405.
22. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting
qualitative research (COREQ): a 32-item checklist for interviews and
focus groups. Int J Qual Health Care 2007;19:349–57.
23. Carr Z, Clarke M, Akl EA, et al. Using the grade approach to support
the development of recommendations for public health interventions
in radiation emergencies. Radiat Prot Dosimetry 2016;171:144–55.
24. World Health Organization, World Health Organization, Reproductive
Health and Research. WHO recommendations: optimizing health
worker roles to improve access to key maternal and newborn health
interventions through task shifting.[internet]. 2012 http://www.ncbi.
nlm.nih.gov/books/NBK148518/ (cited 5 Mar 2018).
25. WHO. Transforming and scaling up health professionals’ education
and training. World Health Organization Guidelines 2013.[Internet.
Geneva: World Health Organization, 2013. http://whoeducation
guidelines.org/sites/default/files/uploads/WHO_EduGuidelines_
20131202_web.pdf. (cited 2018 Mar 3).
26. Hoffman SJ, Røttingen J-A, Bennett S, et al. A Review of Conceptual
Barriers and Opportunities facing Health Systems Research to inform
a Strategy from the World Health Organization. [internet]. Geneva:
Alliance for Health Policy and Systems Research, 2012. http://www.
who.int/alliance-hpsr/alliancehpsr_backgroundpaperconceptualbar
riersopportunities.pdf. (cited 3 Mar 2018).
27. Gopinathan U, Watts N, Hougendobler D, et al. Conceptual and
institutional gaps: understanding how the WHO can become a more
effective cross-sectoral collaborator. Global Health 2015;11:46.
28. Hoffman SJ. Strengthening global health diplomacy in Canada's
foreign policy architecture: Literature review and key informant
interviews. Canadian Foreign Policy Journal 2010;16:17–41.
29. Interagency Advisory Panel on Research Ethics. TCPS 2 (2014)—
the latest edition of Tri-Council Policy Statement: Ethical conduct
for research involving humans [Internet]. http://www.pre.ethics.gc.
ca/eng/policy-politique/initiatives/tcps2-eptc2/Default/ (cited 1 Mar
2016).
30. Dawson A, Verweij M, Health P. Public Health and Legitimacy: Or
why there is still a place for substantive work in ethics. Public Health
Ethics 2014;7:95–7.

31. Petticrew M. When are complex interventions 'complex'? When are
simple interventions 'simple'? Eur J Public Health 2011;21:397–8.
32. European Centre for Disease Prevention and Control. Evidencebased methodologies for public health - How to assess the best
available evidence when time is limited and there is lack of sound
evidence. [internet]. Stockholm: ECDC, 2011. http://ecdc.europa.eu/
en/publications/publications/1109_ter_evidence_based_methods_
for_public_health.pdf. (cited 30 Nov 2016).
33. Durrheim DN, Reingold A. Modifying the GRADE framework could
benefit public health. J Epidemiol Community Health 2010;64:387.
34. Rehfuess EA, Bruce N, Prüss-Üstün A. GRADE for the advancement
of public health. J Epidemiol Community Health 2011;65:559.
35. Schünemann H, Hill S, Guyatt G, et al. The GRADE approach and
Bradford Hill's criteria for causation. J Epidemiol Community Health
2011;65:392–5.
36. Petticrew M. Time to rethink the systematic review catechism?
Moving from 'what works' to 'what happens'. Syst Rev 2015;4:36.
37. Petticrew M, Anderson L, Elder R, et al. Complex interventions and
their implications for systematic reviews: a pragmatic approach. J
Clin Epidemiol 2013;66:1209–14.
38. Petticrew M, Rehfuess E, Noyes J, et al. Synthesizing evidence
on complex interventions: how meta-analytical, qualitative, and
mixed-method approaches can contribute. J Clin Epidemiol
2013;66:1230–43.
39. Movsisyan A, Melendez-Torres GJ, Montgomery P. A harmonized
guidance is needed on how to "properly" frame review questions
to make the best use of all available evidence in the assessment
of effectiveness of complex interventions. J Clin Epidemiol
2016;77:139–41.
40. Guyatt GH, Schünemann HJ, Djulbegovic B, et al. Guideline panels
should not GRADE good practice statements. J Clin Epidemiol
2015;68:597–600.
41. Glenton C, Lewin S, Gülmezoglu AM. Expanding the evidence base
for global recommendations on health systems: strengths and
challenges of the OptimizeMNH guidance process. Implement Sci
2016;11:98.
42. Squires JE, Valentine JC, Grimshaw JM. Systematic reviews of
complex interventions: framing the review question. J Clin Epidemiol
2013;66:1215–22.
43. Guise JM, Chang C, Butler M, et al. AHRQ series on complex
intervention systematic reviews-paper 1: an introduction to a series
of articles that provide guidance and tools for reviews of complex
interventions. J Clin Epidemiol 2017;90:6–10.
44. Schünemann HJ, Cuello C, Akl EA, et al. GRADE guidelines: 18. How
ROBINS-I and other tools to assess risk of bias in nonrandomized
studies should be used to rate the certainty of a body of evidence. J
Clin Epidemiol 2018.
45. Langlois EV, Tunçalp Ö, Norris SL, et al. Qualitative evidence to
improve guidelines and health decision-making. Bull World Health
Organ 2018;96–79–79A.
46. Movsisyan A, Melendez-Torres GJ, Montgomery P. Users identified
challenges in applying GRADE to complex interventions and
suggested an extension to GRADE. J Clin Epidemiol 2016;70:191–9.
47. Movsisyan A, Melendez-Torres GJ, Montgomery P. Outcomes in
systematic reviews of complex interventions never reached "high"
GRADE ratings when compared with those of simple interventions. J
Clin Epidemiol 2016;78:22–33.
48. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for
assessing risk of bias in non-randomised studies of interventions.
BMJ 2016;355:i4919.
49. Lewin S, Glenton C, Munthe-Kaas H, et al. Using qualitative
evidence in decision making for health and social interventions: an
approach to assess confidence in findings from qualitative evidence
syntheses (GRADE-CERQual). PLoS Med 2015;12:e1001895.
50. Rosenbaum SE, Moberg J, Glenton C, et al. Developing Evidence to
Decision Frameworks and an Interactive Evidence to Decision Tool
for Making and Using Decisions and Recommendations in Health
Care: Global Challenges:1700081.
51. WHO. WHO recommendations on antenatal care for a positive
pregnancy experience [Internet: World Health Organization,
2016. http://apps.who.int/iris/bitstream/handle/10665/250796/
9789241549912-eng.pdf?sequence=1. (cited 3 Mar 2018).
52. WHO. Health worker roles in providing safe abortion care and
post-abortion contraception. [Internet]. Geneva: World Health
Organization, 2015. http://apps.who.int/iris/bitstream/handle/10665/
181041/9789241549264_eng.pdf;jsessionid=D82669E3011AB374
78CD7C0319B02033?sequence=1. (cited 3 Mar 2018).
53. WHO. Retrieval, synthesis and assessment of evidence on complex
health interventions. http://www.who.int/maternal_child_adolescent/
guidelines/development/complex-health-interventions/en/ (cited 19
Apr 2018).

Gopinathan U, Hoffman SJ. BMJ Glob Health 2018;3:e000716. doi:10.1136/bmjgh-2018-000716

13

BMJ Glob Health: first published as 10.1136/bmjgh-2018-000716 on 8 September 2018. Downloaded from http://gh.bmj.com/ on 20 September 2018 by guest. Protected by copyright.

BMJ Global Health

54. Norris SL, Bero L. GRADE Methods for guideline development: time
to evolve? Ann Intern Med 2016;165:810.
55. University of Oxford. GRADE Extension for Complex Social
Interventions [Internet]: Department of Social Policy and Intervention,
2016. https://www.spi.ox.ac.uk/research/details/grade-extension-
for-complex-social-inter.html. (cited 19 Nov 2016).
56. Norris SL, Ford N. Improving the quality of WHO guidelines over
the last decade: progress and challenges. Lancet Glob Health
2017;5:e855–e856.
57. WHO. Draft thirteenth general programme of work 2019–2023.
Promote health, keep the world safe, serve the vulnerable [Internet].
Geneva: World Health Organization, 2018. http://apps.who.int/gb/
ebwha/pdf_files/EB142/B142_3-en.pdf?ua=1. (cited 2 Feb 2018).

14

58. Nordic Consulting Group. Evaluation of WHO’s Normative Function
[Internet]. 2017 http://www.who.int/about/evaluation/who_
normative_function_report_july2017.pdf (cited 1 Dec 2017).
59. Berends L, Johnston J. Using multiple coders to enhance qualitative
analysis: The case of interviews with consumers of drug treatment.
Addict Res Theory 2005;13:373–81.
60. Armstrong D, Gosling A, Weinman J, et al. The place of inter-rater
reliability in qualitative research: an Empirical Study. Sociology
1997;31:597–606.
61. Mays N, Pope C. Rigour and qualitative research. BMJ
1995;311:109–12.
62. Barbour RS. Checklists for improving rigour in qualitative research: a
case of the tail wagging the dog? BMJ 2001;322:1115–7.

Gopinathan U, Hoffman SJ. BMJ Glob Health 2018;3:e000716. doi:10.1136/bmjgh-2018-000716

BMJ Glob Health: first published as 10.1136/bmjgh-2018-000716 on 8 September 2018. Downloaded from http://gh.bmj.com/ on 20 September 2018 by guest. Protected by copyright.

BMJ Global Health

